Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

- 1 Article Summary Line: Evidence of increasing dengue endemicity in Florida: Vector
- 2 surveillance during dengue and West Nile virus outbreaks revealed widespread presence of other
- 3 dengue virus serotypes in the absence of local index cases.
- 4 **Running Title:** Dengue and West Nile Virus outbreak in Florida
- 5 Keywords: Dengue virus, West Nile Virus, Arboviruses, Disease Vectors, Disease Outbreaks,

6 COVID-19

- 7 Title: A molecular surveillance-guided vector control response to concurrent dengue and West
- 8 Nile virus outbreaks in a COVID-19 hotspot of Florida
- 9 Authors: Heather Coatsworth¹, Catherine A. Lippi, Chalmers Vasquez, Jasmine B. Ayers,
- 10 Caroline J. Stephenson, Christy Waits, Mary Florez, André B. B. Wilke, Isik Unlu, Johana
- 11 Medina, Maria L. Alcaide, Sadie J. Ryan, John A. Lednicky, John C. Beier, William Petrie,
- 12 Rhoel R. Dinglasan²
- 13 ¹Corresponding author for review purposes only
- 14 ²Corresponding author
- 15 Corresponding Author: Rhoel R. Dinglasan, University of Florida, 2055 Mowry Rd,
- 16 Gainesville, FL 32611, USA, rdinglasan@epi.ufl.edu, (+1) 352-294-8448

17 Author Affiliations:

- 18 University of Florida, Gainesville, Florida, USA (H. Coatsworth, C. Lippi, J. B. Ayers, C. J.
- 19 Stephenson, C. Waits, M. Florez, S. J. Ryan, J, A. Lednicky, R. R. Dinglasan)

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

20 Miami-Dade Mosquito Control District, Miami, Florida, USA (C. Vasquez, I. Unlu, J. Medina,

21 W. Petrie)

22 University of Miami, Miami, Florida, USA (A. B. B. Wilke, M. L. Alcaide, J. C. Beier)

23 Navy Entomology Center of Excellence, Jacksonville, FL USA (C. Waits)

24 Abstract

25 Simultaneous dengue virus (DENV) and West Nile virus (WNV) outbreaks in Florida, USA, in 2020 resulted in 71 dengue virus serotype 1 and 86 WNV human cases. Our outbreak 26 response leveraged a molecular diagnostic screen of mosquito populations for DENV and WNV 27 in Miami-Dade County to quickly employ targeted mosquito abatement efforts. We detected 28 29 DENV serotypes 2 and 4 in mosquito pools, highlighting the silent circulation of diverse dengue serotypes in mosquitoes. Additionally, we found WNV-positive mosquito pools in areas with no 30 historical reports of WNV transmission. These findings demonstrate the importance of proactive, 31 32 strategic arbovirus surveillance in mosquito populations to prevent and control outbreaks, particularly when other illnesses (e.g., COVID-19), which present with similar symptoms are 33 34 circulating concurrently. Growing evidence for substantial infection prevalence of dengue in 35 competent mosquito vectors in the absence of local index cases suggests a higher level of dengue 36 endemicity in Florida than previously thought.

37 Introduction

Although West Nile Virus (WNV) is endemic in the continental United States, only a
handful of states, especially Florida, are at risk of autochthonous dengue virus (DENV)
transmission (1,2). Throughout 2020, Miami-Dade County was the epicenter of COVID-19 in

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

41 Florida, but unbeknownst to the general U.S. population, the state experienced in parallel,

42 concurrent outbreaks of DENV and WNV from May - December 2020, resulting in 71 local

43 cases of dengue fever (DENV serotype 1) and 86 cases of WNV. Herein, we report the outcome

44 of vector surveillance and control effort in response to the arbovirus outbreaks in Miami-Dade

45 County (August- November 2020).

46 Methods

47 Sample collection and processing

Adult mosquitoes were collected with BG-Sentinel traps (Biogents AG, Regensburg, Germany)
baited with dry ice, for 24 hours. Miami-Dade Mosquito Control District (MDMCD) trapped,
morphologically identified, and sorted adult female mosquitoes by location into pools of 2-25
mosquitoes of the same species. Samples were kept cold to avoid RNA degradation, shipped on
dry ice, and stored at -80°C. In total, 743 pools were collected for testing [548 for DENV (pools
of *Aedes aegypti* and *Aedes albopictus*, N= 5,079 mosquitoes) and 188 for WNV (pools of *Anopheles crucians, Culex coronator, Culex nigripalpus,* and *Culex quinquefasciatus*, N= 2,589

55 mosquitoes)].

56 RNA extraction

57 Chilled, sterile 1X phosphate-buffered saline (PBS) and sterile glass beads were added to 58 each sample in a biosafety cabinet (BSC). Each 1 mL sample was homogenized in a Bullet 59 Blender (speed 8, 5 minutes) with repeated cooling on ice/cold block in the BSC. Samples were 60 centrifuged (3,750xg, 3 minutes) and 140 μ L of the homogenate supernatant was added to AVL 61 lysis buffer (560 μ L) (Qiagen). RNA was extracted using the QIAmp Viral RNA extraction kit 62 (Qiagen) following the manufacturer's protocols with 2x40 μ L elution steps. One pool of 5

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

uninfected Ae. aegypti (Orlando) mosquitoes was processed in parallel, serving as a negative 63 extraction control to rule out contamination or spurious amplification.

Real-Time RT-PCR Virus Detection

64

65

66 Sample RNA was either tested for i) WNV or ii) DENV based on the mosquito species for a given pool. Samples designated for DENV screening were first run through a pan-dengue 67 serotype screen, DENVAll (Appendix Table 1), while the remaining samples were screened via a 68 69 WNV assay (Appendix Table 2). Each sample, prepared in a PCR hood with static air, was run as technical duplicates. Each plate included a mosquito extraction control, a no template control, 70 and either i) a positive WNV control or ii) dengue virus serotype 1, 2, 3 and 4 (DENV-1 through 71 72 DENV-4) positive controls. All positive RNA controls were obtained from BEI resources diluted 73 1:10 (Appendix Tables 1,2,5). Analyses used either QuantaBio UltraPlex 1-Step ToughMix (4X) Low-ROX master mix (Appendix Table 3) or SuperScript[™] III Platinum[™] One-Step qRT-PCR 74 75 (Appendix Table 4) on a BioRad CFX96 Touch Real-Time PCR Detection System at 50°C for 76 30 minutes (for Superscript reactions) or 50°C for 10 minutes (for QuantaBio reactions), 95°C for 2 minutes, and 45 cycles of: 95°C for 15 seconds and 60°C for 45 seconds. Both assays 77 yielded similar results, which helped overcome availability bottlenecks during the COVID-19 78 79 pandemic. Samples that were DENV-positive via the DENVAll assay were analyzed for serotype 80 specificity (Appendix Tables 5). Any putative positive or inconclusive (i.e., only one replicate amplified) samples were re-run in confirmatory reactions, adding extra technical replicates and 81 performing additional confirmatory runs as needed to confirm virus positivity. 82

Positive and negative sample designation 83

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

A sample was considered 'positive' based on positive technical duplicate results in two independent runs using the WNV assay (Appendix Table 2) and the DENV serotype-specific assay (Appendix Table 5). Samples were considered 'negative' based on no detectable Ct value in either technical duplicate after 45 cycles.

88 *Mapping mosquito samples*

To understand the spatial distribution of mosquito pools collected for this effort, we 89 90 developed maps using ArcMap (v 10.6) at the zip code level, which is the smallest level of resolution obtainable with our datasets. All datasets were either publicly available: Miami-Dade 91 County Boundaries, population density and land use (2010 US Census, Miami-Dade County's 92 93 Open Data Hub), median household income (2010 US Census, Michigan Population Studies), 94 persons living with HIV/AIDS (PLWH) (2018, AIDsVu), or obtained with permission from personal communications (2018 - 2020 mosquito prevalence c/o Chalmers Vasquez, Miami-95 96 Dade Mosquito Control District; 2009 – 2019 Imported DENV cases c/o Andrea Morrison, 97 Florida Department of Health). Land-use types were manually concatenated to 11 different 98 primary categories: Agricultural, Cemeteries, Commercial, Educational, Industrial, Marine, 99 Recreational, Residential, Paved, Water, and Vacant. These types were further summed as: 100 'urban/built' (Commercial, Educational, Industrial, and Paved), 'agricultural/recreational' 101 (Agricultural, Recreational), 'residential' (Residential) and 'other' (Cemeteries, Marine, Water, and Vacant) (Appendix Table 6). 102

Spatial statistical analysis of vector distribution and spatial visualization of overlapping PLWH
 and arbovirus hotspots

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

105	To explore the spatial relationship between positivity and overall mosquito sampling, the
106	directional distribution and mean center (e.g., central tendencies, dispersion) were computed for
107	DENV- and WNV-positive mosquito pools, for all collected DENV vectors (Ae. aegypti and Ae.
108	albopictus) and all WNV vectors (An. crucians, Cx. coronator, Cx. nigripalpus, and Cx.
109	quinquefasciatus), both individually and together. Kernel density estimation (KDE) with optimal
110	distance bandwidths (3) was used to visualize the continuous density of DENV- and WNV-
111	positive mosquito pools, as well as traps containing un-infected DENV and WNV vectors. To
112	determine whether arbovirus-positive pools occurred in areas where there were imported DENV
113	cases or in areas with a higher number of PLWH, local Moran's I, a local indicator of spatial
114	association (LISA), analyses with inverse distance weighting were performed to detect and
115	identify PLWH hotspots (areas of elevated incidence or prevalence) that potentially overlap with
116	locations of arbovirus positive pools, as well as imported DENV cases for 2019 only, and for the
117	2009-2019 period. All spatial statistical analyses were completed in ArcMap (v 10.6).

118 Results

119 Molecular detection of arbovirus-positive mosquito pools

We found that 2.96% of female mosquito pool samples (22/743 pools, 382/7,668 mosquitoes) were positive for an arbovirus; 4 were DENV-2 positive, 9 were DENV-4 positive (2.43% DENV positivity), and 9 were WNV positive (4.79% WNV positivity) (Table 1 and Appendix 7). Results were confirmed and verified independently by the Florida Department of Health (FLDOH), and the inclusion of a pool of lab reared mosquitoes in every extraction and PCR run ruled out contamination during lab handling or spurious amplification of mosquito material.

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

127 For DENV, we tested 45 *Ae. albopictus* and 510 *Ae. aegypti* mosquito pools, and only *Ae.*

128 *aegypti* pools were found to be positive for DENV-2 and/or DENV-4 (2.43% positivity).

129 For WNV, we tested five *An. crucians*, five *Cx. coronator*, 47 *Cx. nigripalpus* and 131

130 *Cx. quinquefasciatus* pools. Only *Cx. nigripalpus* pools were WNV positive (19.1% positivity),

131 although CDC findings from earlier in 2020 (June), found three positive *Cx. quinquefasciatus*

132 pools.

133 Mosquito pool samples that were found to be DENV- or WNV-positive were reported to

the MDMCD within 48-72 hours. Miami-Dade Mosquito Control Division initiated door-to-door

source reduction in the areas where positive mosquito pools were found. Vectobac WGD (Valent

136 Biosciences), a larvicide product containing *Bacillus thuringiensis israelensis*, was applied at

137 positive pool sites for four weeks. Adulticide treatment using chlorpyrifos was also conducted

138 (weather permitting) using Mosquitomist (Clarke).

A spatial-climatic distribution of arbovirus-positive mosquito pools identified exigent and
emerging areas of concern

141 DENV-positive mosquito pools were distributed throughout the county, with most 142 (11/13) positive pools located in downtown Miami (N=3), Wynwood (N=2), and South Miami (N=6) (Figure 1A) and in areas with mid-to-high human population density (2,000 - 7,000)143 people/km²) (Figure 1B). At the zip code level, DENV-positive pools were primarily found in 144 145 built and residential environments (59.42%) over more rural, (i.e., agricultural and recreational) areas (14.62%) (Figure 1C). Conversely, the thirteen WNV-positive pools (9 identified herein) 146 had three primary infection foci – in Wynwood (N=4), high population density (>3000 147 people/km², urban built environment), in Homestead (N=8), low population density (<470 148

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

149	people/km ² , mostly agricultural and recreational land), and in North Miami (N=1), mid
150	population density $(1,000 - 3,000 \text{ people/km}^2 \text{ and mixed land use})$ (Figure 1D-F). WNV-positive
151	pools were primarily from agricultural and recreational areas (69.32%) and were less common in
152	urban built and residential areas (15.98%).
153	The directional distribution and mean center computations of dengue vector distributions
154	showed that DENV-positive mosquito pools were within the directional distribution of all
155	dengue vector traps (Figure 2A). Ae. aegypti prevalence dominated the traps in much of the
156	county and had a much larger directional distribution than Ae. albopictus, whose presence was
157	concentrated in southern Miami-Dade County (Figure 2B). Although the directional distribution
158	of all WNV vectors overlapped with the directional distribution of the WNV-positive mosquito
159	pools, the latter extended well beyond the southernmost tip of the WNV vector directional ellipse
160	(Figure 2C). Culex quinquefasciatus, An. crucians and Cx. nigripalpus had distinct directional
161	distributions in the Miami Beach area, North Miami, and South Miami, respectively (Figure 2D).
162	The distribution of Cx. coronator encompassed all three of these zones, lacking any strict
163	boundary (Figure 2D).

The KDE maps show a clear high density of vector trapping efforts across Miami-Dade County except for the southernmost area (Appendix Figure 1A). The KDE map for DENV-2 positive pools showed high values surrounding each positive pool but low values between pools (Appendix Figure 1B), while the DENV-4 positive KDE map showed connected high values across all positive pools (Appendix Figure 1C). The KDE map for the WNV vector trapping effort showed a high concentration of vectors in the downtown Miami/Miami Beach areas, with areas of mid values dotted throughout the county (Appendix Figure 1E). The WNV-positive

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

171 pools showed two clear high-value foci, one in Homestead, and one in Miami Beach (Appendix

172 Figure 1F).

DENV-positive mosquito pools were in areas of higher average maximum temperatures,
lower average minimum temperatures, and higher total precipitation (Appendix Figure 2 A-C).
WNV-positive pools displayed the same trend with respect to temperature but were found in
areas of lower total precipitation (Appendix Figure 2D-F).
LISA analyses on imported DENV case data showed similar clusters for both the 2009-

178 2019 imported DENV data (Appendix Figure 3A), as well as the 2019 only imported DENV

179 dataset (Appendix Figure 3B). The northwestern area of Miami-Dade was a high-high cluster,

180 indicating this area is a hotspot for imported DENV cases. Conversely, the Miami Beach area

181 was a low-low cluster, suggesting a consistently lower-than-average number of imported DENV

182 cases (a cold spot). The low-high outliers for both datasets occurred just below the hotspot in

183 northwest Miami-Dade, while the high-low outlier for the decade-wide dataset was in South

184 Miami, and the 2019 only data had high-low outliers throughout North Miami.

185 We explored the possibility of increased arbovirus risk to special populations in Miami-

186 Dade (i.e., PLWH) by examining in parallel the LISA results for PLWH and the spatial

187 distribution of DENV or WNV positive pools and observed that DENV-positive mosquito pools

188 were in the low-low PLWH cluster (Appendix Figure 3C), while one of the WNV-positive pool

189 foci was in a PLWH hotspot (Appendix Figure 3D).

190 Discussion

191 Ecological distribution of WNV-positive mosquito pools

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

192	Although WNV-positive mosquito pools are rarely reported in Miami-Dade County, we
193	found nine positive mosquito pools collected between June – November 2020; three other WNV
194	positive mosquito pools were found in 2020 (collected earlier in June and analyzed by the CDC).
195	All four mosquito species we tested can transmit WNV $(4,5)$; however, we only found WNV-
196	positive Cx. nigripalpus pools, an expected result, as it is the primary enzootic and epidemic
197	vector of mosquito-borne viruses encephalitides such as WNV, St. Louis encephalitis virus, and
198	eastern equine encephalitis virus throughout southern Florida (6). This result is intriguing,
199	considering the overwhelmingly dominant collection of Cx. quinquefasciatus throughout the
200	county. Differences in WNV vector positivity may be due to several factors including host
201	preference and vector competence. Previous reports show that Cx. quinquefasciatus has a wide
202	range of WNV competency that appears to partition according to spatial and climatic scales and
203	is influenced by virus genetic background (7–11).

There appeared to be a centralized distribution of traps collecting *Culex* and *Anopheles* 204 mosquitoes, while positive pool traps were dispersed throughout the county. The spatial 205 partitioning of the WNV-positive mosquito pools suggests that the positive pools had a distinct 206 207 spatial trend within the larger distribution of traps collecting *Culex* and *Anopheles* mosquitoes in Miami-Dade County. This might indicate that current trap coverage is not adequate to reliably 208 detect WNV-positive mosquito pools. As WNV infects a wealth of other non-human animals 209 210 (i.e., horses, alligators, birds, etc.) (12), controlling the spread of WNV requires additional 211 zoonotic measures including implementing equine WNV vaccines, as well as testing dead birds 212 to understand prevalence and virus hotspots throughout the county.

WNV-positive mosquito pools were primarily located in areas with lower precipitation,
higher maximum temperature, and lower minimum temperature (range of 21-29°C), optimal for

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

215 multiple *Culex* vectors (10). As there was no clear overlap between the spatial distribution of

216 WNV vectors and climatic variables, these general climatic conditions are likely ideal for all the

217 WNV vectors we analyzed. WNV-positive mosquito pools were found primarily in agricultural

and recreational areas. These areas include protected bird sanctuaries, as well as habitats for

- resident and migrating shorebirds, which are known WNV avian hosts (12).
- 220 Ecological distribution of DENV-positive mosquito pools

Although other dengue vectors (i.e., Aedes spp.) are present in Miami-Dade (13), our data 221 suggest that Ae. aegypti is clearly the primary vector of concern. Evidence suggests that 222 223 Floridian Ae. aegypti (Monroe County) and Ae. albopictus (Indian River County) are similarly competent for DENV-1 (14). DENV vector competency varies greatly based on DENV serotype 224 and FL Ae. aegypti geographic origin (15), so extrapolations of Ae. aegypti and Ae. albopictus 225 vector competence across FL may not be appropriate. Our findings may be a by-product of Ae. 226 *aegypti* prevalence, as considerably more *Ae. aegypti* were collected than *Ae. albopictus* in traps 227 across the entirety of Miami-Dade County in 2020, and in former years (13). 228

DENV-positive pools were primarily located in areas with higher precipitation, higher maximum temperature, and lower minimum temperature. The directional distribution of DENVpositive pools suggests that the current trap spread is more than adequate to reliably detect DENV-positive pools. However, since trap density within the DENV-positive pool distribution area is not as concentrated as in the other *Aedes* positive trap locales, additional traps in the ellipse margins could prove useful.

235 Epidemiological relevance of WNV-positive mosquito pools

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

236	WNV-positive mosquito pools overlapped with the timing of 27 human symptomatic
237	cases (June, July, August), 33 human asymptomatic blood donors (June, July August), as well as
238	15 WNV-positive birds (June, July), all in Miami-Dade County (16). One of the WNV-positive
239	pool foci overlapped with a hotspot of PLWH (Appendix Figure 3D). This is especially
240	concerning for PLWH, as these individuals are at a higher risk of neurotropism from WNV
241	infection (17–21). WNV positive pools were primarily found in more rural areas with lower
242	median household incomes, and low to medium population density (Figure 1 D-F). Low-income
243	areas have previously been associated with higher WNV prevalence (22,23). These data
244	underscore the need for tailored programs to protect and prevent infection in these at-risk
245	populations.

246 Epidemiological relevance of DENV-positive mosquito pools

In the last five years, the number of local DENV cases in Florida has risen from zero 247 (2017) to 71 (2020). A rise in cases can also be seen in the imported DENV case numbers 248 249 (DENV-1 through DENV-4). In 2017, there were only 18 imported cases, 73 in 2018, 395 in 250 2019, 41 in 2020. This spike in dengue cases was mirrored in Miami-Dade County, where local 251 case numbers moved from zero cases in 2017, to one in 2018, fourteen in 2019 and four in 2020, 252 and travel-associated cases progressed from nine in 2017, to thirty-eight in 2018, 226 in 2019 253 and twenty in 2020. The large spike in imported cases in 2019 may have introduced other DENV 254 serotypes into the resident Miami-Dade mosquito populations, acting as seeding events, which 255 are known drivers of local DENV case incidence (24,25).

To examine whether this could be the case, we analyzed the available zip code-mapped
historical (2009 – 2019) and 2019 imported DENV data using LISA analyses (Appendix Figure

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

258 3A and B), as well as the 2019 only imported DENV dataset (Appendix Figure 3B). The

similarity in the decade-long and 2019 LISA analyses suggests that the high number of imported

cases in 2019 may have driven the hotspot trends seen in our analyses. None of our DENV-

261 positive mosquito pools overlapped with known imported DENV case hotspots. This could be

due to a lack of reporting of zip code level imported DENV data. Alternatively, if mosquitoes

bite individuals outside of their listed area of primary residence, such as where individuals spend

time outdoors, where they work, or where they socialize, the direct overlap would not be

265 observed.

Local human cases of DENV-1, DENV-2 and DENV-3 have been reported in FL 266 (2.16.26–28). In 2020, only DENV-1 local cases were reported, despite our findings of DENV-2 267 and DENV-4 positive mosquito pools in the county. 'Silent' DENV circulation, defined as 268 transmission between DENV asymptomatic individuals, as well as DENV maintenance in the 269 vector population despite no reported human infection, likely represents the majority of 270 transmission events (29). Finding additional DENV serotypes in the absence of a local human 271 index case is not the first instance of silent DENV circulation in Ae. aegypti in the Americas. 272 273 Previous reports have shown that DENV-4 was found in Manatee County, FL in 2018, and DENV-3 was detected in Ae. aegypti in Brazil despite no human index cases (30,31). This silent 274 circulation is likely due to low but persistent vertical transmission in the mosquito population 275 276 (31–33). This disparity could also be due to inherent differences in mosquito vector competence for DENV-1, -2 and -4, as mosquitoes collected in Miami-Dade had higher DENV-1 infection 277 and transmission rates than mosquitoes from Miami-Dade infected with DENV-2 and -4 (15). 278 Although the pathogenicity of the 2020 Miami-Dade human DENV-1 index strain is unknown, 279

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

- the strain may be more infectious to or cause increased disease severity in humans than other
- 281 circulating dengue strains.

282	Having multiple concurrent circulating serotypes puts individuals at an increased risk of
283	DENV infection due to complications arising from immune enhancement $(34,35)$. These risks
284	include dengue fever and severe dengue (dengue hemorrhagic fever and dengue shock
285	syndrome) and can be fatal (36). A woman in her 30's died from DENV-2 in Miami-Dade in
286	2019, and subsequent viral analysis suggested that infection occurred after DENV circulation
287	had occurred in the Miami area (37).
288	There were more DENV-positive pools in areas with lower prevalence of PLWH, higher
289	median household income and mid-high population density (Figure 1A-C, Appendix Figure 3C).
290	Although there does not seem to be evidence for an association between income and DENV
291	prevalence (38), DENV is a known urban-centric disease (39).
292	The perfect storm: arbovirus transmission in a global pandemic
293	Miami Dade County has been a hotspot of SARS-CoV-2 transmission throughout the
294	pandemic, with the highest case rate and death toll in the state. Unfortunately, due to the non-
295	standardized nature of COVID-19 case reporting throughout Florida (reports range from
296	residence-based, testing locale-based and exposure-based), we could not directly map COVID-19
297	prevalence alongside mosquito pool positivity. The potential for immunocompromise resulting
298	from acute SARS-CoV-2 infection to increase severity and/or transmissibility of other diseases
299	(i.e. West Nile, dengue) in the Miami Dade population is concerning.
300	Due to the similar symptoms produced by COVID-19, West Nile, and dengue infection

301 (fever, headache, muscle pain, nausea, vomiting, malaise), symptomatic WNV or DENV

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

infected individuals may have self-quarantined assuming they were positive for COVID-19 and
never received a correct diagnosis. The high number of asymptomatic WNV positive individuals
identified directly through blood donorship suggests that the proportion of asymptomatic WNV
positive human carriers may be high, and previous reports show that the majority of DENV
infected humans are also asymptomatic carriers (29). It should be noted that dengue is not
currently part of routine blood donor screening in Miami-Dade.

The spread of the positive pools is intriguing, as prior arbovirus positive pools (for WNV and Zika virus) in Miami-Dade County were solely concentrated within the Miami Beach, Little River and Wynwood locales. Our data suggest a much wider arbovirus positive pool spread, ranging across the county.

Together, these data highlight a lack of vector containment and the importance of 312 continued surveillance for arboviruses in their vector species. This is especially true when 313 infection risk and continued transmission is increased due to: i) the presence of other illnesses 314 (e.g., COVID-19) that present similarly in a clinic to arbovirus infection, ii) the high incidence of 315 PLWH in areas of known WNV positivity resulting in potentially worse health outcomes 316 following infection, and iii) climatic conditions favoring above-average Ae. aegypti and Cx. 317 318 *nigripalpus* vector indices. The large proportion of asymptomatic WNV cases highlights the critical need for improved DENV diagnostics, as no dengue rapid diagnostic tests are currently 319 cleared for use in the United States (37). Prevention and control measures are imperative to 320 prevent future and expanded DENV and WNV outbreaks; targeted vector control efforts through 321 continued mosquito pathogen screening and subsequent population specific insecticide spraying 322 are necessary to prevent arbovirus spread throughout the county. 323

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

324 Acknowledgments

325	This research was supported in part by U.S. Centers for Disease Control and Prevention
326	(CDC) grant 1U01CK000510-03, Southeastern Regional Center of Excellence in Vector Borne
327	Diseases Gateway Program. The CDC did not have a role in the design of the study, the
328	collection, analysis, or interpretation of data, or writing the manuscript. Christy Waits is a
329	contractor employee of the U.S. Government. This work was prepared as part of her official
330	duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available
331	for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S. Government work as
332	a work prepared by a military Service member or employee of the U.S. Government as part of
333	that person's official duties. The views expressed in this article are those of the authors and do
334	not necessarily reflect the official policy or position of the Department of the Navy, Department
335	of Defense, nor the U. S. Government. The Department of the Navy, Department of Defense, or
336	the U. S. Government did not have a role in the design of the study, the collection, analysis, or
337	interpretation of data, or writing of the manuscript.
338	Author Bio
339	Dr. Coatsworth is a post-doctoral associate at the University of Florida. Her primary
340	research interests include arbovirology, vector biology, and vector-borne disease transmission.
341	References
342	1. Franco C, Hynes NA, Bouri N, Henderson DA. The Dengue Threat to the United States.
343	[cited 2021 Sep 10]; Available from: www.liebertpub.com
0	

Rey JR. Dengue in Florida (USA). Insects 2014, Vol 5, Pages 991-1000 [Internet]. 2014
 Dec 16 [cited 2021 Oct 7];5(4):991–1000. Available from: https://www.mdpi.com/2075-

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

346 4450/5/4/991/htm

347	3.	Fotheringham AS, Brunsdon C, Charlton M. Quantitative Geography: Perspectives on
348		Spatial Data Analysis. 6th ed. London: Sage Publications; 2000.
349	4.	Turell MJ, Sardelis MR, Dohm DJ, O'guinn ML. Potential North American Vectors of
350		West Nile Virus.
351	5.	Unlu I, Kramer WL, Roy AF, Foil LD. Detection of West Nile Virus RNA in Mosquitoes
352		and Identification of Mosquito Blood Meals Collected at Alligator Farms in Louisiana. J
353		Med Entomol [Internet]. 2010 [cited 2021 Sep 10];47(4):625–33. Available from:
354		https://academic.oup.com/jme/article/47/4/625/992551
355	6.	Day JF, Tabachnick WJ, Smartt CT. Factors That Influence the Transmission of West Nile
356		Virus in Florida. J Med Entomol [Internet]. 2015;52(5):743–54. Available from:
357		https://academic.oup.com/jme/article/52/5/743/828059
358	7.	Anderson SL, Richards SL, Tabachnick WJ, Smartt, Chelsea T. Effects of West Nile
359		Virus Dose and Extrinsic Incubation Temperature on Temporal Progression of Vector
360		Competence in Culex pipiens quinquefasciatus. Source J Am Mosq Control Assoc
361		[Internet]. 2010;26(1):103-7. Available from: https://doi.org/10.2987/09-5926.1
362	8.	Richards SL, Lord CC, Pesko KN, Tabachnick WJ. Environmental and biological factors
363		influencingCulex pipiens quinquefasciatusSay (Diptera: Culicidae) vec-tor competence
364		for West Nile virus. Am J Trop Med Hygeine [Internet]. 2010 [cited 2021 Sep
365		10];83(1):126–34. Available from:
366		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912589/pdf/tropmed-83-126.pdf

- 367 9. Keyel AC, Timm OE, Backenson PB, Id CP, Quinones S, Mcdonough KA, et al. Seasonal
- temperatures and hydrological conditions improve the prediction of West Nile virus
- infection rates in Culex mosquitoes and human case counts in New York and Connecticut.
- 2019; Available from: https://doi.org/10.1371/journal.pone.0217854
- 10. Shocket MS, Verwillow AB, Numazu MG, Slamani H, Cohen JM, El Moustaid F, et al.
- 372 Transmission of west nile and five other temperate mosquito-borne viruses peaks at
- temperatures between 23°C and 26°C. Elife. 2020 Sep 1;9:1–67.
- 11. Richards SL, Anderson SL, Lord CC. Vector competence of Culex pipiens
- 375 quinquefasciatus (Diptera: Culicidae) for West Nile virus isolates from Florida. 2014;
- 376 Available from: http://cdo.ncdc.
- 12. Marra P., Griffing S, Caffrey C, Kilpatrick MA, McLean R, Brand C, et al. West Nile
- Virus and Wildlife . Bioscience [Internet]. 2004 [cited 2021 Sep 11];54(5):393–402.
- Available from: https://academic.oup.com/bioscience/article/54/5/393/416853?login=true
- 13. Wilke ABB, Vasquez C, Medina J, Carvajal A, Petrie W, Beier JC. Community
- 381 Composition and Year-round Abundance of Vector species of Mosquitoes make Miami-
- 382 Dade County, Florida a Receptive Gateway for Arbovirus entry to the United states.
- 383 Available from: https://doi.org/10.1038/s41598-019-45337-2
- Richards SL, Anderson SL, Alto BW. Vector Competence of Aedes aegypti and Aedes
 albopictus (Diptera: Culicidae) for Dengue Virus in the Florida Keys. J Med Entomol
 [Internet]. 2012;49(4):942–6. Available from: http://dx.doi.org/10.1603/ME11293
- 15. Stephenson CJ, Coatsworth H, Waits CM, Nazario-Maldonado NM, Mathias DK,

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

- Dinglasan RR, et al. Geographic partitioning of dengue virus transmission risk in Florida.
 prep. 2021;
 Morrison A, Rowe D, McDermott C, Stanek D, Heberlein-Larson L, LaCrue A, et al.
- 10. Monison A, Rowe D, McDennou C, Stanek D, nebeneni-Laison L, LaCiue A,
- 391 Florida Arbovirus Surveillance [Internet]. Available from:
- 392 http://www.floridahealth.gov/diseases-and-conditions/mosquito-borne-
- diseases/_documents/2020-week-53-arbovirus-surveillance-report.pdf
- 17. Klein RS. A Moving Target: The Multiple Roles of CCR5 in Infectious Diseases. 2007;

Available from: https://academic.oup.com/jid/article/197/2/183/809887

18. Pang J, Thein T-L, Lye DC, Leo Y-S. Differential Clinical Outcome of Dengue Infection

among Patients with and without HIV Infection: A Matched Case-Control Study. Am J
Trop Med Hyg. 2015;92(6):1156–62.

- 19. WG G, DH M, JK L, S L, SF Y, WA F, et al. CCR5 deficiency increases risk of
- 400 symptomatic West Nile virus infection. J Exp Med [Internet]. 2006 Jan 23 [cited 2021 Sep

401 20];203(1):35–40. Available from: https://pubmed.ncbi.nlm.nih.gov/16418398/

402 20. JK L, CY L, C G, C J, B J, H J, et al. Genetic deficiency of chemokine receptor CCR5 is a

403 strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts

- 404 in the US epidemic. J Infect Dis [Internet]. 2008 Jan 15 [cited 2021 Sep 20];197(2):262–5.
- 405 Available from: https://pubmed.ncbi.nlm.nih.gov/18179388/
- JK L, DH M, A L, GA F, D K, D F, et al. CCR5 deficiency is a risk factor for early
 clinical manifestations of West Nile virus infection but not for viral transmission. J Infect
- 408 Dis [Internet]. 2010 Jan 15 [cited 2021 Sep 20];201(2):178–85. Available from:

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

- 409 https://pubmed.ncbi.nlm.nih.gov/20025530/
- 410 22. Harrigan RJ, Thomassen HA, Buermann W, Cummings RF, Kahn ME. Economic
- 411 Conditions Predict Prevalence of West Nile Virus. PLoS One [Internet].
- 412 2010;5(11):15437. Available from: www.plosone.org
- 413 23. Rothman SE, Jones JA, LaDeau SL, Leisnham PT. Higher West Nile Virus Infection in
- 414 Aedes albopictus (Diptera: Culicidae) and Culex (Diptera: Culicidae) Mosquitoes From
- Lower Income Neighborhoods in Urban Baltimore, MD. J Med Entomol [Internet]. 2021
- 416 May 15 [cited 2021 Sep 11];58(3):1424–8. Available from:
- 417 https://academic.oup.com/jme/article/58/3/1424/6013060
- 418 24. Guzzetta G, Marques-Toledo CA, Rosà R, Teixeira M, Merler S. Quantifying the spatial
- 419 spread of dengue in a non-endemic Brazilian metropolis via transmission chain

420 reconstruction. Available from: www.nature.com/naturecommunications

- 421 25. Li N, Feng Y, Vrancken B, Chen Y, Dong L, Yang Q, et al. Assessing the impact of
- 422 COVID-19 border restrictions on dengue transmission in Yunnan Province, China: an
- 423 observational epidemiological and phylogenetic analysis. Lancet Reg Heal Pacific
- 424 [Internet]. 2021 [cited 2021 Sep 11];14:100259. Available from:
- 425 https://doi.org/10.1016/j.lanwpc.2021.100259
- 426 26. Trout A, Baracco G, Rodriguez M, Barber J, Leal A, Radke E, et al. Locally Acquired
- 427 Dengue --- Key West, Florida, 2009--2010. Morb Mortal Wkly Rep [Internet]. 2010 [cited
- 428 2021 Oct 7];59(19):577–81. Available from:
- 429 https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5919a1.htm

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

- 430 27. Radke EG, Gregory CJ, Kintziger KW, Sauber-Schatz EK, Hunsperger EA, Gallagher
- 431 GR, et al. Dengue Outbreak in Key West, Florida, USA, 2009. Emerg Infect Dis
- 432 [Internet]. 2012 Jan [cited 2021 Oct 7];18(1):135. Available from:
- 433 /pmc/articles/PMC3310087/
- 434 28. FD T, MN R, KD S, AS G, SF M, S I. Origin of the dengue virus outbreak in Martin
- 435 County, Florida, USA 2013. Virol Reports [Internet]. 2014 Mar 1 [cited 2021 Oct 7];1–
- 436 2(C):2–8. Available from: https://europepmc.org/articles/PMC4318122
- 437 29. Bosch QA ten, Clapham HE, Lambrechts L, Duong V, Buchy P, Althouse BM, et al.
- 438 Contributions from the silent majority dominate dengue virus transmission. PLOS Pathog
- 439 [Internet]. 2018 May 1 [cited 2021 Sep 11];14(5):e1006965. Available from:

440 https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006965

- 441 30. Boyles SM, Mavian CN, Finol E, Ukhanova M, Stephenson CJ, Hamerlinck G, et al.
- 442 Under-the-Radar Dengue Virus Infections in Natural Populations of Aedes aegypti
 443 Mosquitoes. mSphere. 2020 Apr 29;5(2).
- 444 31. Ferreira-De-Lima H, Dos P, Andrade S, Matsumiya Thomazelli L, Toledo Marrelli M,
- 445 Urbinatti PR, et al. Silent circulation of dengue virus in Aedes albopictus (Diptera:
- 446 culicidae) resulting from natural vertical transmission. Available from:
- 447 https://doi.org/10.1038/s41598-020-60870-1
- 448 32. Stephenson CJ, Coatsworth H, Kang S, Lednicky JA, Dinglasan RR. Transmission
- 449 Potential of Floridian Aedes aegypti Mosquitoes for Dengue Virus Serotype 4:
- 450 Implications for Estimating Local Dengue Risk. mSphere [Internet]. 2021 Aug 25 [cited
- 451 2021 Sep 11];6(4). Available from: https://doi.org/10.1128/mSphere

- 452 33. Ayers JB, Xie X, Coatsworth H, Stephenson CJ, Waits M, Shi P-Y, et al. Ecology and
- 453 transmission of a dengue virus serotype 4 identified in 1 wild Aedes aegypti in Florida 2.
- 454 Available from: https://doi.org/10.1101/2021.07.11.451177
- 455 34. Cummings DAT, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic effects of
- 456 antibody-dependent enhancement on the fitness of viruses [Internet]. 2005. Available
- 457 from: www.pnas.orgcgidoi10.1073pnas.0507320102
- 458 35. Recker M, Blyuss KB, Simmons CP, Tinh Hien T, Wills B, Farrar J, et al. Immunological
- 459 serotype interactions and their effect on the epidemiological pattern of dengue Hospital for
- 460 Tropical Diseases, 190 Ben. Available from: http://rspb.royalsocietypublishing.org.
- 461 36. Gubler DJ. Dengue and Dengue Hemorrhagic Fever. Clin Microbiol Rev.
- 462 1998;11(3):480–96.
- 37. Sharp TM, Morris S, Morrison A, de Lima Corvino D, Santiago GA, Shieh W, et al. Fatal
 Dengue Acquired in Florida. N Engl J Med. 2021;(384):2257–9.
- 465 38. Mulligan K, Dixon J, Sinn C-LJ, Elliott SJ. Is dengue a disease of poverty? A systematic
 466 review.
- 467 39. Gubler DJ. Dengue, Urbanization and Globalization: The Unholy Trinity of the 21st
- 468 Century. Trop Med Health. 2011;39(4):3–11.
- 469 Supplementary Information
- 470 *Contamination troubleshooting*

- 471 We noted issues with DENV-2 amplification in the no template and mosquito extraction negative
- 472 controls with the CDC DENV-2 serotype-specific RT-qPCR assay for a few of the mosquito
- 473 pools. We addressed these concerns using standard contamination troubleshooting protocols:
- 474 preparing all qPCR reactions in a PCR hood, deep cleaning qPCR preparation areas, creating
- new primer and probe dilutions, and using different primer and probe stocks. We also tested each
- 476 assay reagent for inherent DENV-2 RNA/cDNA contamination but did not find any evidence of
- 477 contamination. Due to these issues, a new DENV-2 serotype specific assay was implemented
- 478 (see DENV2 Alm, Supplementary Table 5) targeting a different region of the DENV-2 E
- 479 glycoprotein. No amplification of negative controls was seen with the new primer-probe
- 480 combination.

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

- 481 Table 1. Positive mosquito pool results from screening mosquitoes collected in Miami-Dade
- 482 County (Florida, USA) in 2020. WNV = West Nile virus, DENV-2 = dengue virus serotype 2,
- 483 DENV-4 = dengue virus serotype 4

Collection Date	Sample ID	Overall sample result	Species	Pool Size
06/09/20	N/A*	WNV positive	Culex quinquefasciatus	18
06/23/20		WNV positive	Culex quinquefasciatus	4
		WNV positive	Culex quinquefasciatus	24
06/30/20		WNV positive	Culex quinquefasciatus	5
07/23/20	0723-30	WNV positive	Culex nigripalpus	25
	0723-31	WNV positive	Culex nigripalpus	25
	0723-39	WNV positive	Culex nigripalpus	25
	0723-44	WNV positive	Culex nigripalpus	25
07/30/20	0730-37	DENV-2 positive	Aedes aegypti	25
	0730-41	DENV-2 positive	Aedes aegypti	25
08/20/20	0820-06	WNV positive	Culex nigripalpus	25
	0820-07	WNV positive	Culex nigripalpus	25
	0820-08	WNV positive	Culex nigripalpus	25
	0820-09	WNV positive	Culex nigripalpus	25
	0820-11	WNV positive	Culex nigripalpus	25
08/28/20	0828-2	DENV-2 positive	Aedes aegypti	23
	0828-10	DENV-2 positive	Aedes aegypti	25
09/17/20	0917-4	DENV-4 positive	Aedes aegypti	13
	0917-8	DENV-4 positive	Aedes aegypti	8
	0917-11	DENV-4 positive	Aedes aegypti	8
	0917-12	DENV-4 positive	Aedes aegypti	4
	0917-13	DENV-4 positive	Aedes aegypti	10
	0917-16	DENV-4 positive	Aedes aegypti	3
	0917-27	DENV-4 positive	Aedes aegypti	6
09/22/20	0922-2	DENV-4 positive	Aedes aegypti	5
09/29/20	0929-07	DENV-4 positive	Aedes aegypti	2

⁴⁸⁴

*Pathogen detection conducted by the CDC.

485 Figure 1. Spatial distribution of arbovirus positive mosquito pools (purple – DENV, orange –

486 WNV). A and D: Positive pool spread throughout Miami-Dade County – DENV positive pools

(A), or WNV positive pools (D). B and E: Positive pool spread overlayed on 2010 Miami-Dade

488 population density (individuals/km2) – DENV positive pools (B), or WNV positive pools (E). C

and F: Positive pool spread overlayed on 2010 Miami-Dade land use data – DENV positive

490 pools (C) or WNV positive pools (F).

491 Figure 2. Spatial analysis of A: DENV positive pool distribution (purple) within traps containing

492 DENV vectors (black), B: Distribution of traps containing *Aedes aegypti* (purple) or *Aedes*

493 *albopictus* (pink), C: WNV positive pool distribution (orange) within traps containing WNV

494 vectors (black), D: Distribution of traps containing *Culex quinquefasciatus* (dark orange), *Culex*

495 *nigripalpus* (light orange), *Culex coronator* (yellow), or *Anopheles crucians* (brown).

496

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

497 Appendix

498 For Appendix Tables 1, 2. and 5: Positive controls used were the following: DENV-1:NR-

499 50530, DENV-2: NR-50531, DENV-3: NR-50532, DENV-4: NR-50533, and WNV: NR-50434.

Limits of quantification (LOQs) were determined by standard curve analysis of diluted RNApositive controls

502 **Appendix Table 1.** Pan-dengue Real-Time RT-PCR assay (assay courtesy of an active 503 collaboration with Dr. Remi Charrel (Aix Marseille University)

Description	Name	Sequence	Fluor/ Quencher	Position	Product size (bp)	Target	Limit of quantification (LOQ)	
Dengue All 1 Forward	DenAll-1 For	AGGACYAGAGGTTAGAGGAGA		DENV1: 10590 - 10610 DENV2: 10579 - 10599 DENV3: 10564 - 10584 DENV4: 10506 - 10526	(0p)			
Dengue All 1 Reverse	DenAll-1 Rev	CGYTCTGTGCCTGGAWTGAT		DENV1: 10697 - 10678 DENV2: 10685 - 10666 DENV3: 10479 - 10499 DENV4: 10611 - 10592	DENV1: 108 DENV2: 107 DENV3: 106 DENV4: 106	DENV sfRNA	DENV1: 30 copies/µL DENV2: 279 copies/µL DENV3: 66 copies/µL	
Dengue All 1 Probe	DenAll-1 Probe	ACAGCATATTGACGCTGGGARA GACC	FAM/BHQ- 1	DENV1: 10629 - 10654 DENV2: 10617 - 10642 DENV3: 10601 - 10626 DENV4: 10543 - 10568	_		DENV4: 20.1 copies/µL	
Dengue All 2 Forward	DenAll-2 For	GGACTAGAGGTTAGAGGAGACC CC		DENV1: 10591 - 10614 DENV2: 10580 - 10603 DENV3: 10565 -	DENV1: 81 DENV2: 80 DENV3: 79 DENV4: 79	DENV sfRNA	-	

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

				10588	
				DENV4:	
				10507 -	
				10530	
				DENV1:	
				10671 -	
				10651	
				DENV2:	
				10659 -	
Dengue All	DenAll-2	CACACACCACCATCTCCCC		10639	
2 Reverse	Rev	GAGACAGCAGGATCTCTGGTC		DENV3:	
				10643 -	
				10623	
				DENV4:	
				10585 -	
				10565	
				DENV1:	
				10633 -	
				10650	
				DENV2:	
				10619 -	
Dengue All	DenAll-2	AGCATATTGACGCTGGGA	FAM/BHQ-	10636	
2 Probe	Probe	AGCATATIGACGCIGGGA	1	DENV3:	
				10583 -	
				10600	
				DENV4:	
				10545 -	
				10562	

504

505 Appendix Table 2. West Nile Virus Real-Time RT-PCR assay (courtesy of Dr. Thomas

506 Unnasch, University of South Florida)

Description	Name	Sequence	Fluor/ Quencher	Position	Product size (bp)	Target	Limit of quantification (LOQ)
WNV A forward	10668F	CAGACCACGCTACGGC		10668 -			
primer	10000	G		10684			
WNV A reverse	10770R	CTAGGGCCGCGTGGG		10770 -	103	WNV	1.5 x 10 ⁻⁶ ng
primer	10770K	014000000001000		10756	103	3'UTR	1.5 X 10 Hg
WNV A probe	WNV A	CTGCGGAGAGTGCAGT	FAM/BHQ-	10691 -	_		
WINV A PIODE	probe	CTGCGAT	1	10714			

507

- 508 Appendix Table 3. Reaction volumes for each assay using 1-step qRT-PCR using QuantaBio
- 509 UltraPlex 1-Step ToughMix (4X) Low-ROX master mix. Volumes are representative of one
- 510 25µL reaction. Primer and probes were diluted to working solutions of 10µM for assay use. Final
- 511 primer and probe concentrations/reaction are denoted by []

Assay	Assay Reagent Volume (in µL)		
Dengue serotype specific –	Water	10.3	
Dengue 1	4X Reaction mix	6.25	
	Dengue 1 forward primer [10µM]	2.5 [Final conc. 1µM]	
	Dengue 1 reverse primer [10µM]	2.5 [Final conc. 1µM]	
	Dengue 1 probe [10µM]	0.45 [Final conc. 0.18µM]	
	Template	3	

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

Dengue serotype specific –	Water	12.8
Dengue 2	4X Reaction mix	6.25
	Dengue 2 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 2 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 2 probe [10µM]	0.45 [Final conc. 0.18µM]
	Template	3
Dengue serotype specific -	Water	10.3
Dengue 3	4X Reaction mix	6.25
	Dengue 3 forward primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 3 reverse primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 3 probe [10µM]	0.45 [Final conc. 0.18µM]
	Template	3
Dengue serotype specific –	Water	12.8
Dengue 4	4X Reaction mix	6.25
	Dengue 4 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 4 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 4 probe [10µM]	0.45 [Final conc. 0.18µM]
	Template	3
West Nile Virus	Water	11.6
	4X Reaction mix	6.25
	WNV A forward primer [10µM]	0.9375 [Final conc. 0.375µM]
	WNV A reverse primer [10µM]	0.9375 [Final conc. 0.375µM]
	WNV A 4 probe [10µM]	0.3125 [Final conc. 0.125µM]
	Template	5
Dengue All	Water	7.75
	2X Reaction mix	6.25
	DENVAII-1 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-1 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-1 probe [10µM]	0.50 [Final conc. 0.2µM]
	DENVAII-2 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-2 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-2 probe [10µM]	0.50 [Final conc. 0.2µM]
	Template	5

512

- 513 Appendix Table 4. Reaction volumes for each assay using SuperScript[™] III Platinum[™] One-
- 514 Step qRT-PCR Kit. Volumes are representative of one 25µL reaction. Primer and probes were
- 515 diluted to working solutions of $10\mu M$ for assay use. Final primer and probe
- 516 concentrations/reaction are indicated []

Assay	Reagent	Volume (in µL)
Dengue serotype specific –	Water	3.55
Dengue 1	2X Reaction mix	12.5
	Dengue 1 forward primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 1 reverse primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 1 probe [10µM]	0.45 [Final conc. 0.18µM]
	RT/Platinum Taq	0.5
	Template	3
Dengue serotype specific -	Water	6.05
Dengue 2	2X Reaction mix	12.5
	Dengue 2 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 2 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 2 probe [10µM]	0.45 [Final conc. 0.18µM]
	RT/Platinum Taq	0.5
	Template	3
Dengue serotype specific -	Water	3.55

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

Dengue 3	2X Reaction mix	12.5
	Dengue 3 forward primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 3 reverse primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 3 probe [10µM]	0.45 [Final conc. 0.18µM]
	RT/Platinum Taq	0.5
	Template	3
Dengue serotype specific –	Water	6.05
Dengue 4	2X Reaction mix	12.5
	Dengue 4 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 4 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	Dengue 4 probe [10µM]	0.45 [Final conc. 0.18µM]
	RT/Platinum Taq	0.5
	Template	3
West Nile Virus	Water	4.8125
	2X Reaction mix	12.5
	WNV A forward primer [10µM]	0.9375 [Final conc. 0.375µM]
	WNV A reverse primer [10µM]	0.9375 [Final conc. 0.375µM]
	WNV A 4 probe [10µM]	0.3125 [Final conc. 0.125µM]
	RT/Platinum Taq	0.5
	Template	5
Dengue All	Water	3.0
	2X Reaction mix	12.5
	DENVAII-1 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-1 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-1 probe [10µM]	0.50 [Final conc. 0.2µM]
	DENVAII-2 forward primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-2 reverse primer [10µM]	1.25 [Final conc. 0.5µM]
	DENVAII-2 probe [10µM]	0.50 [Final conc. 0.2µM]
	RT/Platinum Taq	0.5
	Template	3
Alm Dengue 2 serotype specific	Water	3.55
	2X Reaction mix	12.5
	Dengue 2 forward primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 2 reverse primer [10µM]	2.5 [Final conc. 1µM]
	Dengue 2 probe [10µM]	0.45 [Final conc. 0.18µM]
	RT/Platinum Taq	0.5
	Template	3

517

518 Appendix Table 5. Serotype-specific assays, including both CDC (Santiago et al., 2013,

doi:10.1371/journal.pntd.0002311) and Alm dengue 2 serotype-specific assays (Alm et al., 2015,

doi: 10.1186/s12879-015-1226-z). "Alm" is used to refer to the publication describing the assay

521 primers and probe to differentiate it from the CDC DENV-2 target

Description	Name	Sequence	Fluor/ Quencher	Position	Product size (bp)	Target	Limit of quantification (LOQ)
Dengue 1 forward primer	D1-F_CDC	CAAAAGGAAGTCGYGCAATA		8936- 8955			
Dengue 1 reverse primer	D1-R_CDC	CTGAGTGAATTCTCTCTGCT RAAC		9023- 9047	112	DENV 1 NS5	3 copies/µL
Dengue 1 probe	D1-Pr_CDC	CATGTGGYTGGGAGCRCGC	FAM/BH Q-1	8961- 8979			
Dengue 2 forward primer	D2-F_CDC	CAGGCTATGGCACYGTCACG AT		1426- 1447	70	DENV	27.9 copies/
Dengue 2 reverse primer	D2-R_CDC	CCATYTGCAGCARCACCATC TC		1482- 1504	78	2 E	μL

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

Dengue 2 probe	D2-Pr_CDC	CTCYCCRAGAACGGGCCTC	FAM/BH	1454-			
Dengue 2 Alm forward primer	DENV2_Alm F	GACTTCAA GCAGAAACACAACATGGAAC RATAGT	Q-1	1480 1873- 1898			
Dengue 2 Alm reverse primer	DENV2_Alm _R	TGATGTAGCTGTCTCCRAAT GG		2050- 2071	199	DENV 2 E	27.9 copies/ µL
Dengue 2 Alm probe	DENV2_Alm _probe	TCAACATAGAAGCAGAACC	FAM/BH Q-1	2030- 2048			·
Dengue 3 forward primer	D3-F_CDC	GGACTRGACACACGCACCCA		701-720	74	DENV 3 prM	66 copies/ µL
Dengue 3 reverse primer	D3-R_CDC	CATGTCTCTACCTTCTCGAC TTGYCT		749-775			
Dengue 3 probe	D3-Pr_CDC	ACCTGGATGTCGGCTGAAG GAGCTTG	FAM/BH Q-1	722-747			
Dengue 4 forward primer	D4-F_CDC	TTGTCCTAATGATGCTRGTC G		884-904			
Dengue 4 reverse primer	D4-R_CDC	TCCACCYGAGACTCCTTCCA		953-973	89	DENV 4 prM	20.1 copies/ µL
Dengue 4 probe	D4-Pr_CDC	TYCCTACYCCTACGCATCGC ATTCCG	FAM/BH Q-1	939-965		•	

522

523 **Appendix Table 6.** Summed categories of land use description types from the 2010 US Census

Land Use Description	Summed Category
Agriculture, Other (Exotic Birds, Monkeys, Research Facilities).	Agricultural
Fallow.	Agricultural
Farm Storage Areas (Storage Structures or Lots for Farm Implements).	Agricultural
Fish Farms (Includes Tropical Fish Aquariums, Fish and Alligator Farms).	Agricultural
Groves.	Agricultural
Horse Training and Stables.	Agricultural
Pasture (Grazing, Animal Farming, Dairy Farms and Animal Feed Lots), excluding Horse and Poultry.	Agricultural
Plant Nurseries (Includes Sod Farms and Ornamental Nurseries).	Agricultural
Poultry.	Agricultural
Row and Field Cropland.	Agricultural
Cemeteries.	Cemeteries
Marine commercial (includes private commercial [non-recreational] marinas and repair yards on public or private land).	Commercial
Office and/or Business and other services (ground level) / Residential (upper levels). Low-density < 15 dwellings per acre or 4 floors.	Commercial
Office Building.	Commercial
Office/Business/Hotel/Residential. Substantial components of each use present. Treated as any combination of the mentioned uses with a hotel as part of development.	Commercial
Sales and Services (Wholesale facilities, Spot commercial, strip commercial, neighborhood shopping centers/plazas). Excludes office facilities.	Commercial
Shopping Centers (Regional and Community).	Commercial
Colleges and Universities, Including Research Centers, Public and Private.	Educational
Private Schools, Including Playgrounds (K-12, Vocational Ed., Day Care and Child Nurseries).	Educational
Public Schools, Including Playgrounds (K-12, Vocational Ed., Day Care and Child Nurseries).	Educational
Antenna Arrays.	Industrial
Communications (Radio, TV, Cable, and Phone), excluding Antenna Arrays.	Industrial
Electric Power (Generator and Substation, and Service Yards).	Industrial

Extraction, Excavation, Quarrying, Rock-Mining, excluding the resulting water body (see 917).	
Extraction, Excavation, Quanying, Nock-winning, excluding the resulting water body (see 917).	Industrial
Industrial Extensive.	Industrial
Industrial intensive, Commercial Condominium type of use.	Industrial
Industrial Intensive, heavy-light manufacturing, and warehousing-storage type of use.	Industrial
Industrial Intensive, Office type of use.	Industrial
Junk Yard.	Industrial
Major Approved Projects.	Industrial
Major Transmission Lines.	Industrial
Oil and Gas Storage (Tank Farms).	Industrial
Sewerage Treatment Plants.	Industrial
Solid Waste Disposal and Transfer (Includes Dumps, Solid Waste Land Fills, Resource Recovery Plants and Facilities, Trash Transfer Stations).	Industrial
Water Supply Plants.	Industrial
Wellfields.	Industrial
Canal right-of-way.	Marine
Coastal Water (Bay only) within Biscayne Bay National Park (Excluding Ocean Waters.	Marine
Coastal Water (Bay only) within the Biscayne Bay Urban Aquatic Preserve (Excluding Ocean Waters).	Marine
Coastal Water (Ocean only) within Biscayne National Park (Excluding Bay Waters).	Marine
Coastal Waters within Everglades National Park.	Marine
Inland water bodies (Lakes, Ponds, and Watercourses) associated with industrial areas, industrial parks, and new industrial development.	Marine
Inland water bodies (Lakes, Rock Pits) associated with extraction, excavation, quarrying and rock-mining activities.	Marine
Inland water bodies (Lakes, Watercourses) associated with residential developments. Marina complexes (docks, piers, moorings, ramps, boat lifts and hoists, boat maintenance and repair, boat storage, fueling operations) for recreational craft located within Parks and Preserves and other small craft harbor complexes used primarily for recreation.	Marine Marine
Other inland water bodies (Lakes, Ponds, Watercourses other than rivers and canals), including road borrow pits.	Marine
Remaining Bay Waters (Excluding Ocean).	Marine
Remaining Ocean Waters (Excluding Bay).	Marine
rtemanning e bean tratere (Exelicating Eay).	Morino
Rivers and Canals (Water)	Marine
Rivers and Canals (Water). Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B).	Marine
Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis	
Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B).	Marine
Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches.	Marine Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. 	Marine Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. 	Marine Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. 	Marine Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. 	Marine Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great 	Marine Recreational Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout Camps, Private Recreational Camps). Includes private tennis courts and pools that are part of the recreational 	Marine Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout 	Marine Recreational Recreational Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout Camps, Private Recreational Camps). Includes private tennis courts and pools that are part of the recreational complex. Private Recreational Facilities Associated with private Residential Developments, except marinas/yacht basins, 	Marine Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout Camps, Private Recreational Camps). Includes private tennis courts and pools that are part of the recreational complex. Private Recreational Facilities Associated with private Residential Developments, except marinas/yacht basins, includes landscape and open spaces associated to residential, commercial and office developments. 	Marine Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout Camps, Private Recreational Camps). Includes private tennis courts and pools that are part of the recreational complex. Private Recreational Facilities Associated with private Residential Developments, except marinas/yacht basins, includes landscape and open spaces associated to residential, commercial and office developments. Recreational Vehicle Parks/Camps. 	Marine Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout Camps, Private Recreational Camps). Includes private tennis courts and pools that are part of the recreational complex. Private Recreational Facilities Associated with private Residential Developments, except marinas/yacht basins, includes landscape and open spaces associated to residential, commercial and office developments. Recreational Vehicle Parks/Camps. Sports Stadiums, Arenas, and Tracks. 	Marine Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout Camps, Private Recreational Camps). Includes private tennis courts and pools that are part of the recreational complex. Private Recreational Facilities Associated with private Residential Developments, except marinas/yacht basins, includes landscape and open spaces associated to residential, commercial and office developments. Recreational Vehicle Parks/Camps. Sports Stadiums, Arenas, and Tracks. Mobile Home Parks and Permanent Mobile Homes. Multi-Family, High Density (Over 25 DU/Gross Acre). 	Marine Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational
 Water Conservation Areas (Properties owned by SFWMD; Big Cypress national preserve, Everglades, and Francis Taylor WMA (also known as conservation areas 3A and 3B). Beaches. Biscayne National Park. County Operated Parks. Cultural (auditoriums, convention centers, exhibition centers, museums, art galleries, libraries). Everglades National Park. Golf courses, Public and Private. Municipal Operated Parks. Other Nature Preserves and Protected Areas (State Mangrove Preserves, Turkey Point Wilderness Area, Great Cypress Swamp Preserves, and acquired government owned EEL sites). Private Recreational Camps/Areas not associated with private Residential Developments (Boy Scout/Girl Scout Camps, Private Recreational Camps). Includes private tennis courts and pools that are part of the recreational complex. Private Recreational Facilities Associated with private Residential Developments, except marinas/yacht basins, includes landscape and open spaces associated to residential, commercial and office developments. Recreational Vehicle Parks/Camps. Sports Stadiums, Arenas, and Tracks. Mobile Home Parks and Permanent Mobile Homes. 	Marine Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational Recreational

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

Residential predominantly (condominium/ rental apartments with lower floors Office and/or Retail. High density > 15 dwelling units per ac, multi-story buildings (Generally more than 5 stories).	Residential
Residential SFgovernment-owned or government subsidized multi-family residential or elderly housing	Residential
Single-Family, High Density (Over 5 DU/Gross Acre, other than Townhouses, Duplexes and Mobile Homes).	Residential
Single-Family, Low-Density (Under 2 DU/Gross Acre).	Residential
Single-Family, MedDensity (2-5 DU/Gross Acre).	Residential
Townhouses.	Residential
TRANSIENT-RESIDENTIAL (HOTEL-MOTEL)	Residential
Two-Family (Duplexes).	Residential
Governmental/Public Administration (Other than Military or Penal).	Commercial
Hospitals, clinics, medical offices and/or dental facilities	Commercial
Houses of Worship and Religious, and associated uses (parking, retreat houses, residencies, childcare, etc.).	Commercial
Military Facilities.	Industrial
Nursing homes, Assisted living facilities, and Adult congregate living quarters	Commercial
Penal and Correctional.	Commercial
Social Services, and Charitable institutions (Shrines, Elks, Moose, Lions Club).	Commercial
Airports (other than Military and Small Grass Airports).	Industrial
Bus/Truck/Freight Forwarding Terminals.	Industrial
Highways and Expressways right-of-way and associated open and landscaped areas excluding paved expressways and ramps.	Paved
Ocean Ship Terminals and Port Facilities, Bay and River Based.	Marine
Parking - Public and Private Garages and Lots.	Paved
Paved Highways, Expressways and Ramps.	Paved
Private Drives.	Paved
Railroads - Terminals, Trackage, and Yards.	Paved
Road Maintenance and Storage Yards, and Motor Pools.	Paved
Small Grass Airports (Includes Crop Dusting Activities).	Industrial
Street right-of-way and entrance features both public and private, and utility easements.	Paved
Streets and Roads, except Expressways and Private Drives.	Paved
TRANSPORTATION, COMMUNICATION, AND UTILITIES	Industrial
Vacant Government owned or controlled.	Vacant
Vacant, Non-Protected, Privately-Owned.	Vacant
Vacant, Protected, Government-Owned or controlled. EEL sites included	Vacant
Vacant, Protected, Privately-Owned. Proposed and designated EEL sites until acquired or protected under any other conservation or environmental mechanism.	Vacant

524

525 Appendix Table 7. WNV-positive and DENV-positive samples

Sample	Sample Designation	Replicate #	Ct value	Avg Ct	Assay Run	Positive Control (1:10)	Positive Control Avg Ct
0723-30	WNV positive	1	39.78		WNV Run 1	WNV	26.05
		2	41.77				26.01
		1	45.49		WNV Run 2	WNV	23.74
		2	43.48				23.77
0723-31	WNV positive	1	38.18		WNV Run 1	WNV	26.05
		2	36.56				26.01
		1	37.52		WNV Run 2	WNV	23.74
		2	42.73				23.77
0723-39	WNV positive	1	32.69		WNV Run 1	WNV	26.05

		2 1	33.11 33.31		WNV Run 2	WNV	26.01 23.74
		2	32.99			VVINV	23.74
0723-44	WNV positive	1	29.33		WNV Run 1	WNV	26.05
		2	29.5				26.01
		1	28.66		WNV Run 2	WNV	23.74
		2	28.6				23.77
0820-06	WNV positive	1	15.11		WNV Run 1	WNV	24.26
		2	15				24.42
		1	13.98		WNV Run 2	WNV	23.74
		2	14.08				23.77
0820-07	WNV positive	1	32.88		WNV Run 1	WNV	24.26
		2	32.75				24.42
		1	31.43		WNV Run 2	WNV	23.74
		2	31.22				23.77
0820-08	WNV positive	1	36.06		WNV Run 1	WNV	24.26
		2	38.35				24.42
		1	35.96		WNV Run 2	WNV	23.74
		2	36				23.77
0820-09	WNV positive	1	37.82		WNV Run 1	WNV	24.26
		2	37.02				24.42
		1	35.88		WNV Run 2	WNV	23.74
0000 44		2	34.74				23.77
0820-11	WNV positive	1 2	39.66 41.72		WNV Run 1	WNV	24.26 24.42
		1	39.45		WNV Run 2	WNV	24.42
		2	38.42			VVINV	23.74
		1	43.27		WNV Run 2	WNV	23.74
		2	Neg				23.77
0730-37	DENV-2 positive	1	Neg	N/A	DENV1 serotype	DENV-1	28.42
	BEITT E poolato	2	Neg		specific Run 1	DERVI	28.47
		1	33.7	33.78	DENV2 serotype	DENV-2	25.06
		2	33.86		specific Run 1		24.78
		1	Neg	N/A	DENV3 serotype	DENV-3	30.49
		2	Neg		specific Run 1		30.38
		1	Neg	N/A	DENV4 serotype	DENV-4	27.88
		2	Neg		specific Run 1		28.08
		1	37.47	36.62	DENV2 serotype	DENV-2	23.96
		2	35.77		specific Run 2		24.10
0730-41	DENV-2 positive	1	Neg	N/A	DENV1 serotype	DENV-1	28.42
		2	Neg		specific Run 1		28.47
		1	27.21	27.205	DENV2 serotype	DENV-2	25.06
		2	27.20		specific Run 1		24.78
		1	Neg	N/A	DENV3 serotype	DENV-3	30.49
		2	Neg		specific Run 1		30.38
		1	Neg	N/A	DENV4 serotype	DENV-4	27.88
		2	Neg		specific Run 1		28.08
		1	29.11	29.15	DENV2 serotype	DENV-2	23.96
	BBHH <i>L</i> A	2	29.19		specific Run 2		24.10
0828-2	DENV-2 positive	1	38.97	38.97	DENVAll Run 1	DENV-1	28.90
							29.13
						DENV-2	24.75
		0	Nee				24.91
		2	Neg			DENV-3	32.37
							32.32
						DENV-4	28.83
		1	Neg	N/A	DENI/1 corotypo		28.79 30.51
		1 2	Neg Neg	IN/A	DENV1 serotype specific Run 1	DENV-1	30.51 30.82
		1	32.35	32.43	DENV2 serotype	DENV-2	27.63

		2	32.51		specific Run 1		27.47
		1	Neg	N/A	DENV3 serotype	DENV-3	32.47
		2	Neg		specific Run 1	-	32.61
		1	Neg	N/A	DENV4 serotype	DENV-4	29.74
		2	Neg		specific Run 1	DENT	29.74
		1	31.35	31.505	DENV2 serotype	DENV-2	27.12
		2	31.66	51.505	specific Run 2	DEINVEZ	26.78
0000 10	DENV-2 positive			37.87	-	DENV-1	
0828-10	DENV-2 positive	1	Neg	37.87	DENVAll Run 1	DEINV-1	28.90
							29.13
						DENV-2	24.75
		_					24.91
		2	37.87			DENV-3	32.37
							32.32
						DENV-4	28.83
							28.79
		1	Neg	N/A	DENV1 serotype	DENV-1	30.51
		2	Neg		specific Run 1		30.82
		1	31.45	31.455	DENV2 serotype	DENV-2	27.63
		2	31.46		specific Run 1		27.47
		1	Neg	N/A	DENV3 serotype	DENV-3	32.47
		2	Neg		specific Run 1		32.61
		1	Neg	N/A	DENV4 serotype	DENV-4	29.74
		2	Neg		specific Run 1		29.74
		1	30.43	30.485	DENV2 serotype	DENV-2	27.12
		2	30.54		specific Run 2		26.78
0917-4	DENV-4 positive	1	34.7	34.7	DENVAll Run 1	DENV-1	31.24
							31.02
						DENV-2	25.67
							26.01
		2	Neg			DENV-3	30.19
							30.38
						DENV-4	29.49
							29.22
		1	41.18	39.735	DENVAll Run 2	DENV-1	32.26
							32.37
						DENV-2	
						DENV-2	27.28
		2	38.29				27.28 27.57
		2	38.29			DENV-2 DENV-3	27.28 27.57 33.38
		2	38.29			DENV-3	27.28 27.57 33.38 34.10
		2	38.29				27.28 27.57 33.38 34.10 32.02
				N/A	DENV1 serotype	DENV-3 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28
		1	Neg	N/A	DENV1 serotype	DENV-3	27.28 27.57 33.38 34.10 32.02 32.28 31.84
		1 2	Neg Neg		specific Run 1	DENV-3 DENV-4 DENV-1	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97
		1 2 1	Neg Neg Neg	N/A N/A	specific Run 1 DENV2 serotype	DENV-3 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28
		1 2 1 2	Neg Neg Neg Neg	N/A	specific Run 1 DENV2 serotype specific Run 1	DENV-3 DENV-4 DENV-1 DENV-2	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43
		1 2 1 2 1	Neg Neg Neg Neg Neg		specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype	DENV-3 DENV-4 DENV-1	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75
		1 2 1 2 1 2	Neg Neg Neg Neg Neg Neg	N/A N/A	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53
		1 2 1 2 1 2 1	Neg Neg Neg Neg Neg 37.46	N/A	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype	DENV-3 DENV-4 DENV-1 DENV-2	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88
		1 2 1 2 1 2 1 2	Neg Neg Neg Neg Neg 37.46 38.03	N/A N/A 37.745	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58
		1 2 1 2 1 2 1 2 1 2 1	Neg Neg Neg Neg Neg 37.46 38.03 Neg	N/A N/A	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52
		1 2 1 2 1 2 1 2 1 2 1 2	Neg Neg Neg Neg 37.46 38.03 Neg Neg	N/A N/A 37.745 N/A	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 26.58 27.52 27.77
		1 2 1 2 1 2 1 2 1 2 1 2 1	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03	N/A N/A 37.745	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 26.58 27.52 27.77 27.02
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03 37.65	N/A N/A 37.745 N/A 36.34	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype specific Run 3	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03	N/A N/A 37.745 N/A	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04 31.24
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03 37.65	N/A N/A 37.745 N/A 36.34	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype specific Run 3	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-4 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04 31.24 31.02
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03 37.65	N/A N/A 37.745 N/A 36.34	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype specific Run 3	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04 31.24 31.02 25.67
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03 37.65 Neg	N/A N/A 37.745 N/A 36.34	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype specific Run 3	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-4 DENV-4 DENV-1 DENV-2	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04 31.24 31.02 25.67 26.01
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03 37.65	N/A N/A 37.745 N/A 36.34	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype specific Run 3	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-4 DENV-4	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04 31.24 31.02 25.67 26.01 30.19
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03 37.65 Neg	N/A N/A 37.745 N/A 36.34	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype specific Run 3	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-4 DENV-4 DENV-1 DENV-2 DENV-3	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04 31.24 31.02 25.67 26.01 30.19 30.38
0917-8	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	Neg Neg Neg Neg 37.46 38.03 Neg Neg 35.03 37.65 Neg	N/A N/A 37.745 N/A 36.34	specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype specific Run 1 DENV4 serotype specific Run 2 DENV4 serotype specific Run 3	DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-4 DENV-4 DENV-1 DENV-2	27.28 27.57 33.38 34.10 32.02 32.28 31.84 31.97 28.28 26.43 30.75 30.53 26.88 26.58 27.52 27.77 27.02 27.04 31.24 31.02 25.67 26.01 30.19

		1	42.04	42.32	DENVAll Run 2	DENV-1	32.26 32.37
						DENV-2	27.28
							27.57
		2	42.6			DENV-3	33.38
		2	42.0			DENVO	34.10
						DENV-4	32.02
						DENV-4	32.28
		1	Neg	N/A	DENV1 serotype	DENV-1	31.84
		2	Neg	IN/A	specific Run 1		31.97
		1	Neg	N/A	DENV2 serotype	DENV-2	28.28
		2	-	IN/A	••	DENV-2	26.43
		2 1	Neg	N/A	specific Run 1		30.75
		2	Neg	IN/A	DENV3 serotype	DENV-3	30.53
			Neg 40.53	38.95	specific Run 1	DENV-4	26.88
		1		30.95	DENV4 serotype specific Run 1	DEINV-4	26.58
		2	37.37	20.40			
		1	Neg	39.19	DENV4 serotype	DENV-4	27.52
		2	39.19	20.0	specific Run 2		27.77
		1	38.82	38.9	DENV4 serotype	DENV-4	27.02
		2	38.98		specific Run 3		27.04
0917-11	DENV-4 positive	1	33.14	33.12	DENVAll Run 1	DENV-1	31.24
							31.02
						DENV-2	25.67
		_					26.01
		2	33.09			DENV-3	30.19
							30.38
						DENV-4	29.49
							29.22
		1	Neg	N/A	DENV1 serotype	DENV-1	31.84
		2	Neg		specific Run 1		31.97
		1	Neg	N/A	DENV2 serotype	DENV-2	28.28
		2	Neg		specific Run 1		26.43
		1	Neg	N/A	DENV3 serotype	DENV-3	30.75
		2	Neg		specific Run 1		30.53
		1	38.09	37.96	DENV4 serotype	DENV-4	26.88
		2	37.82		specific Run 1		26.58
		1	Neg	40.38	DENV4 serotype	DENV-4	27.52
		2	40.38		specific Run 2		27.77
		1	37.16	36.98	DENV4 serotype	DENV-4	27.02
		2	36.80		specific Run 3		27.04
0917-12	DENV-4 positive	1	33.47	33.05	DENVAll Run 1	DENV-1	31.24
							31.02
						DENV-2	25.67
							26.01
		2	32.63			DENV-3	30.19
							30.38
						DENV-4	29.49
							29.22
		1	Neg	N/A	DENV1 serotype	DENV-1	31.84
		2	Neg		specific Run 1		31.97
		1	Neg	N/A	DENV2 serotype	DENV-2	28.28
		2	Neg		specific Run 1		26.43
		1	Neg	N/A	DENV3 serotype	DENV-3	30.75
		2	Neg		specific Run 1		30.53
		2	Neg	37.55	DENV4 serotype	DENV-4	26.88
		2	37.55	51.55	specific Run 1		26.58
		2 1		41.54			
		2	42.13 40.94	41.04	DENV4 serotype	DENV-4	27.52
				25.00	specific Run 2		27.77
		1	36.04	35.92	DENV4 serotype	DENV-4	27.02
0047.40		2	35.79	00.40	specific Run 3		27.04
0917-13	DENV-4 positive	1	32.84	33.42	DENVAll Run 1	DENV-1	31.24

							31.02
						DENV-2	25.67
						DEINV-2	
		0	22.00				26.01
		2	33.99			DENV-3	30.19
							30.38
						DENV-4	29.49
		4	Nee	N1/A			29.22
		1	Neg	N/A	DENV1 serotype	DENV-1	31.84
		2	Neg		specific Run 1		31.97
		1	Neg	N/A	DENV2 serotype	DENV-2	28.28
		2	Neg		specific Run 1		26.43
		1	Neg	N/A	DENV3 serotype	DENV-3	30.75
		2	Neg		specific Run 1		30.53
		1	Neg	38.46	DENV4 serotype	DENV-4	26.88
		2	38.46		specific Run 1		26.58
		1	40.29	40.50	DENV4 serotype	DENV-4	27.52
		2	40.7		specific Run 2		27.77
		1	38.75	37.99	DENV4 serotype	DENV-4	27.02
		2	37.23		specific Run 3		27.04
0917-16	DENV-4 positive	1	35.95	37.09	DENVAll Run 1	DENV-1	31.24
							31.02
						DENV-2	25.67
							26.01
		2	38.23			DENV-3	30.19
							30.38
						DENV-4	29.49
							29.22
		1	Neg	N/A	DENV1 serotype	DENV-1	31.84
		2	Neg		specific Run 1		31.97
		1	Neg	N/A	DENV2 serotype	DENV-2	28.28
		2	Neg		specific Run 1		26.43
		1	Neg	N/A	DENV3 serotype	DENV-3	30.75
		2	Neg		specific Run 1		30.53
		1	36.57	36.57	DENV4 serotype	DENV-4	26.88
		2	Neg		specific Run 1		26.58
		1	39.41	40.94	DENV4 serotype	DENV-4	27.52
		2	42.46		specific Run 2		27.77
		1	35.05	35.50	DENV4 serotype	DENV-4	27.02
		2	35.94	00.00	specific Run 3	DEIT	27.04
0917-27	DENV-4 positive	1	36.42	36.42	DENVAll Run 1	DENV-1	31.24
0317-27	DEINV-4 positive	1	50.42	50.42	DENVALINUT		31.02
						DENV-2	25.67
						DEINV-2	26.01
		2	Neg				30.19
		2	Neg			DENV-3	
							30.38
						DENV-4	29.49
		4	New	N1/A			29.22
		1	Neg	N/A	DENVAll Run 2	DENV-1	32.26
							32.37
						DENV-2	27.28
		_					27.57
		2	Neg			DENV-3	33.38
							34.10
						DENV-4	32.02
							32.28
		1	Neg	N/A	DENV1 serotype	DENV-1	31.84
		2	Neg		specific Run 1		31.97
		1	Neg	N/A	DENV2 serotype	DENV-2	28.28
		2	Neg		specific Run 1		26.43
		1	Neg	N/A	DENV3 serotype	DENV-3	30.75
		2	Neg		specific Run 1		30.53

Reserved space. Do not place any text in this section. Include the mandatory author checklist or your manuscript will be returned. Use *continuous* line numbering in your manuscript.

		1	36	36.33	DENV4 serotype	DENV-4	26.88
		2	36.65		specific Run 1		26.58
		1	Neg	38.29	DENV4 serotype	DENV-4	27.52
		2	38.29		specific Run 2		27.77
		1	37.12	37.45	DENV4 serotype	DENV-4	27.37
		2	37.77		specific Run 3		27.16
0922-2	DENV-4 positive	1	33.91	34.28	DENVAll Run 1	DENV-1	31.24
							31.02
						DENV-2	25.67
							26.01
		2	34.64			DENV-3	30.19
							30.38
						DENV-4	29.49
							29.22
		1	Neg	N/A	DENV1 serotype	DENV-1	31.84
		2	Neg		specific Run 1		31.97
		1	Neg	N/A	DENV2 serotype	DENV-2	28.28
		2	Neg		specific Run 1		26.43
		1	Neg	N/A	DENV3 serotype	DENV-3	30.75
		2	Neg		specific Run 1		30.53
		1	36.11	35.72	DENV4 serotype	DENV-4	26.88
		2	35.33		specific Run 1		26.58
		1	36.75	37.51	DENV4 serotype	DENV-4	27.52
		2	38.26		specific Run 2		27.77
		1	35.08	35.17	DENV4 serotype	DENV-4	27.02
		2	35.25		specific Run 3		27.04
0929-07	DENV-4 positive	2	35.25 Neg	38.87	specific Run 3 DENVAll Run 1	DENV-1	27.04 31.11
0929-07	DENV-4 positive		35.25 Neg	38.87	specific Run 3 DENVAll Run 1	DENV-1	31.11
0929-07	DENV-4 positive			38.87		DENV-1 DENV-2	
0929-07	DENV-4 positive			38.87			31.11 31.14 26.75
0929-07	DENV-4 positive	1		38.87		DENV-2	31.11 31.14
0929-07	DENV-4 positive		Neg	38.87			31.11 31.14 26.75 26.70 32.47
0929-07	DENV-4 positive	1	Neg	38.87		DENV-2	31.11 31.14 26.75 26.70
0929-07	DENV-4 positive	1	Neg	38.87		DENV-2 DENV-3	31.11 31.14 26.75 26.70 32.47 32.44 30.46
0929-07	DENV-4 positive	1	Neg 38.87		DENVAll Run 1	DENV-2 DENV-3 DENV-4	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75
0929-07	DENV-4 positive	1	Neg	38.87		DENV-2 DENV-3	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26
0929-07	DENV-4 positive	1	Neg 38.87		DENVAll Run 1	DENV-2 DENV-3 DENV-4 DENV-1	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37
0929-07	DENV-4 positive	1	Neg 38.87		DENVAll Run 1	DENV-2 DENV-3 DENV-4	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28
0929-07	DENV-4 positive	1 2 1	Neg 38.87 Neg		DENVAll Run 1	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57
0929-07	DENV-4 positive	1	Neg 38.87		DENVAll Run 1	DENV-2 DENV-3 DENV-4 DENV-1	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38
0929-07	DENV-4 positive	1 2 1	Neg 38.87 Neg		DENVAll Run 1	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10
0929-07	DENV-4 positive	1 2 1	Neg 38.87 Neg		DENVAll Run 1	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02
0929-07	DENV-4 positive	1 2 1 2	Neg 38.87 Neg 40.23	40.23	DENVAll Run 1 DENVAll Run 2	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28
0929-07	DENV-4 positive	1 2 1 2 1	Neg 38.87 Neg 40.23 Neg		DENVAll Run 1 DENVAll Run 2 DENV1 serotype	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37
0929-07	DENV-4 positive	1 2 1 2 1 2 1 2	Neg 38.87 Neg 40.23 Neg Neg	40.23 N/A	DENVAll Run 1 DENVAll Run 2 DENV1 serotype specific Run 1	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-1	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37 29.47
0929-07	DENV-4 positive	1 2 1 2 1 2 1 2 1	Neg 38.87 Neg 40.23 Neg Neg Neg	40.23	DENVAll Run 1 DENVAll Run 2 DENV1 serotype specific Run 1 DENV2 serotype	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37 29.47 28.28
0929-07	DENV-4 positive	1 2 1 2 1 2 1 2 1 2	Neg 38.87 Neg 40.23 Neg Neg Neg Neg Neg	40.23 N/A N/A	DENVAll Run 1 DENVAll Run 2 DENV1 serotype specific Run 1 DENV2 serotype specific Run 1	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37 29.47 28.28 29.47 28.28 26.43
0929-07	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1	Neg 38.87 Neg 40.23 Neg Neg Neg Neg Neg Neg Neg	40.23 N/A	DENVAll Run 1 DENVAll Run 2 DENV1 serotype specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-1	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37 29.47 28.28 29.47 28.28 26.43 30.26
0929-07	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2	Neg 38.87 Neg 40.23 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg	40.23 N/A N/A N/A	DENVAll Run 1 DENVAll Run 2 DENV1 serotype specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1	DENV-2 DENV-3 DENV-4 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-2	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37 29.47 28.28 29.37 29.47 28.28 26.43 30.26 30.06
0929-07	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	Neg 38.87 Neg 40.23 Neg Neg Neg Neg Neg Neg Neg Neg Neg 38.84	40.23 N/A N/A	DENVAll Run 1 DENVAll Run 2 DENVAll Run 2 DENV2 serotype specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1 DENV4 serotype	DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37 29.47 28.28 29.37 29.47 28.28 26.43 30.26 30.06 27.37
0929-07	DENV-4 positive	1 2 1 2 1 2 1 2 1 2 1 2	Neg 38.87 Neg 40.23 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg	40.23 N/A N/A N/A	DENVAll Run 1 DENVAll Run 2 DENV1 serotype specific Run 1 DENV2 serotype specific Run 1 DENV3 serotype specific Run 1	DENV-2 DENV-3 DENV-4 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-2	31.11 31.14 26.75 26.70 32.47 32.44 30.46 30.75 32.26 32.37 27.28 27.57 33.38 34.10 32.02 32.28 29.37 29.47 28.28 29.37 29.47 28.28 26.43 30.26 30.06

526

527 Appendix Figure 1. Kernel density estimation (KDE) of uninfected vector populations and

528 arbovirus positive mosquito pools (purple – DENV, orange – WNV). A: KDE on traps that

529 collected DENV vectors, B: KDE on all DENV positive pools, C: KDE on all DENV-2 positive

- pools, D: KDE on all DENV-4 positive pools, E: KDE on traps that collected WNV vectors, F:
- 531 KDE on WNV positive pools.
- 532 Appendix Figure 2. Yearly temperature and precipitation maps for Miami-Dade County in 2020
- 533 overlayed with arbovirus positive mosquito pools (purple DENV, orange WNV). A and D:
- 534 Maximum average temperature for 2020 in Miami-Dade visualized with DENV positive pools
- (A) or WNV positive pools (D). B and E: Minimum average temperature for 2020 in Miami-
- 536 Dade visualized with DENV positive pools (B) or WNV positive pools (E). C and F: Total
- precipitation in Miami-Dade in 2020 visualized with DENV positive pools (C) or WNV positive
 pools (F).
- 539 Appendix Figure 3. Local Moran's I, a local indicator of spatial association (LISA), analyses of
- 540 imported DENV cases and PLWH overlayed with arbovirus positive mosquito pools (purple –
- 541 DENV, orange WNV). A: LISA from DENV imported cases (2009 2019) visualized with
- 542 2020 DENV positive pools, B: LISA from 2019 DENV imported cases visualized with 2020
- 543 DENV positive pools, C: LISA from PLWH visualized with 2020 DENV positive pools, D:
- 544 LISA from PLWH visualized with 2020 WNV positive pools.









